Update your tester profile Login
  • Register with Our Database

    Get started on the volunteer process by registering your basic information with our database. This information is provided to help us determine your eligibility for current and future studies. We will not share or sell this info with any third party. 

    Thanks for your interest, you'll find the intake form here

  • Study 1415: Healthy Male and Female Particpants

    Research Purpose: Study 1415 is designed to evaluate an investigational drug being developed for the treatment of certain types of inflammatory conditions. A single dose of the investigational drug will be given as a subcutaneous injection (just under the skin) and will be compared to similar versions of the drug which are approved to be prescribed in the U.S. and Europe (adalimumab/Humira®).  The following will be evaluated:

    • How quickly the body process and eliminates the investigational drug compared to the U.S and E.U. approved versions
    • The safety/tolerability of the investigational drug compared to the U.S and E.U. approved versions
    • The body’s immune response to the investigational drug compared to the U.S and E.U. approved versions

    Minimum Screening Qualifications:

    Males

    Men are allowed to participate

    Females

    Women are allowed to participate

    Age

    18-45 years

    Body Mass Index (BMI)

    19 and 30.5

    Weight

    Greater than 132 pounds

    Tobacco/Nicotine Use

    No tobacco/nicotine 24 hours prior to in-house stay or while at the research unit.  Use of tobacco/nicotine products at all other times during the study is allowed.

    Drug Testing

    Must test negative for drugs of abuse. 

    Alcohol/Drug Abuse History

    No history of drug or alcohol abuse within 5 year of the screening appointment.

    Health History

    Must be healthy; not being evaluated or treated for any medical conditions unless otherwise approved on a case by case basis by the study doctor

    Restricted Medications

    No required regular use of any prescription medications, non-prescription medications, vitamins, or herbal supplements not listed below

    Allowed Medications

    Acetaminophen and prescribed/stable hormonal birth control are allowed.

     

    Study Time Commitment: For participants who qualify based on screening evaluation, study participation will last for approximately 10 ½ weeks. 

    Inpatient Stays

    • Participants will admit for an inpatient stay at Prism Clinical Research 1 time.
    • The inpatient stay will last approximately 8 ½ days (8 overnights)

    Outpatient Visits

    • There are at total of 9 outpatient visits
    • The outpatient visits will last between approximately 1-2 hours

     Compensation: Up to $2950.00

  • Study 1409: Healthy Male and Female (Not of Child Bearing Potential) Participants

    Research Purpose:  Study 1409 is designed to evaluate the dosing method of an investigational drug being developed for the treatment of psoriasis. The investigational drug will be given by subcutaneous (just below the skin) injection to healthy participants two times via syringe (once using 1 syringe and once using two syringes). The following will be evaluated:

    • How much of the investigational drug gets into the blood stream using both injection methods
    • How quickly the investigational drug enters and eliminates from the blood stream using both injection methods
    • The safety/tolerability of the investigational drug

     

    Minimum Screening Qualifications:

    Males

    Men are allowed to participate

    Females

    Women are allowed to participate only if they are postmenopausal or surgically sterilized by hysterectomy, tubal ligation, or bilateral oophorectomy

    Age

    18-55 years

    Body Mass Index (BMI)

    18 and 30

    Weight

    110 and 242 pounds

    Tobacco/Nicotine Use

    No tobacco/nicotine use during In-house stays and outpatient visits.  Use of tobacco/nicotine products at all other times during the study is allowed.

    Drug Testing

    Must test negative for drugs of abuse. 

    Alcohol/Drug Abuse History

    No history of drug or alcohol abuse within 1 year of the screening appointment.

    Health History

    Must be healthy; not being evaluated or treated for any medical conditions unless otherwise approved on a case by case basis by the study doctor

    Restricted Medications

    No required regular use of any prescription medications, non-prescription medications, or vitamins not listed below

    Allowed Medications

    Hormone replacement therapy, thyroid medications, acetaminophen

     

    Study Time Commitment: For participants who qualify based on screening evaluation, study participation will last for approximately 9 weeks. 

    In-house Stays

    Participants will stay at Prism Clinical Research two times. 

    • In-house Stay 1:  2 ½ days (2 overnights)
    • In-house Stay 2: 1 ½ days (1 overnight).  This stay will take place approximately 1 month after the first In-house stay

    Office Visits

    Each In-house stay is followed by a set of brief office visits.

    • In-house Stay 1 is followed by 9 office visits over the course of 4 weeks
    • In-house Stay 2 is followed by 10 office visits over the course of 4 weeks and one follow up phone call. 

    Compensation: Up to $2500

Current Studies

Contact a Recruiter

  • Kevin Fitzgerald
    651-289-2098 Email Me

    Recruiter extaordinaire.

  • Molly Hair
    651-289-2096 Email Me
  • Kerry Bunkers
    651-289-2097 Email Me

    Recruiter extraordinaire! 

     

  • Register with Our Database

    Get started on the volunteer process by registering your basic information with our database. This information is provided to help us determine your eligibility for current and future studies. We will not share or sell this info with any third party. 

    Thanks for your interest, you'll find the intake form here

  • Study 1415: Healthy Male and Female Particpants

    Research Purpose: Study 1415 is designed to evaluate an investigational drug being developed for the treatment of certain types of inflammatory conditions. A single dose of the investigational drug will be given as a subcutaneous injection (just under the skin) and will be compared to similar versions of the drug which are approved to be prescribed in the U.S. and Europe (adalimumab/Humira®).  The following will be evaluated:

    • How quickly the body process and eliminates the investigational drug compared to the U.S and E.U. approved versions
    • The safety/tolerability of the investigational drug compared to the U.S and E.U. approved versions
    • The body’s immune response to the investigational drug compared to the U.S and E.U. approved versions

    Minimum Screening Qualifications:

    Males

    Men are allowed to participate

    Females

    Women are allowed to participate

    Age

    18-45 years

    Body Mass Index (BMI)

    19 and 30.5

    Weight

    Greater than 132 pounds

    Tobacco/Nicotine Use

    No tobacco/nicotine 24 hours prior to in-house stay or while at the research unit.  Use of tobacco/nicotine products at all other times during the study is allowed.

    Drug Testing

    Must test negative for drugs of abuse. 

    Alcohol/Drug Abuse History

    No history of drug or alcohol abuse within 5 year of the screening appointment.

    Health History

    Must be healthy; not being evaluated or treated for any medical conditions unless otherwise approved on a case by case basis by the study doctor

    Restricted Medications

    No required regular use of any prescription medications, non-prescription medications, vitamins, or herbal supplements not listed below

    Allowed Medications

    Acetaminophen and prescribed/stable hormonal birth control are allowed.

     

    Study Time Commitment: For participants who qualify based on screening evaluation, study participation will last for approximately 10 ½ weeks. 

    Inpatient Stays

    • Participants will admit for an inpatient stay at Prism Clinical Research 1 time.
    • The inpatient stay will last approximately 8 ½ days (8 overnights)

    Outpatient Visits

    • There are at total of 9 outpatient visits
    • The outpatient visits will last between approximately 1-2 hours

     Compensation: Up to $2950.00

  • Study 1409: Healthy Male and Female (Not of Child Bearing Potential) Participants

    Research Purpose:  Study 1409 is designed to evaluate the dosing method of an investigational drug being developed for the treatment of psoriasis. The investigational drug will be given by subcutaneous (just below the skin) injection to healthy participants two times via syringe (once using 1 syringe and once using two syringes). The following will be evaluated:

    • How much of the investigational drug gets into the blood stream using both injection methods
    • How quickly the investigational drug enters and eliminates from the blood stream using both injection methods
    • The safety/tolerability of the investigational drug

     

    Minimum Screening Qualifications:

    Males

    Men are allowed to participate

    Females

    Women are allowed to participate only if they are postmenopausal or surgically sterilized by hysterectomy, tubal ligation, or bilateral oophorectomy

    Age

    18-55 years

    Body Mass Index (BMI)

    18 and 30

    Weight

    110 and 242 pounds

    Tobacco/Nicotine Use

    No tobacco/nicotine use during In-house stays and outpatient visits.  Use of tobacco/nicotine products at all other times during the study is allowed.

    Drug Testing

    Must test negative for drugs of abuse. 

    Alcohol/Drug Abuse History

    No history of drug or alcohol abuse within 1 year of the screening appointment.

    Health History

    Must be healthy; not being evaluated or treated for any medical conditions unless otherwise approved on a case by case basis by the study doctor

    Restricted Medications

    No required regular use of any prescription medications, non-prescription medications, or vitamins not listed below

    Allowed Medications

    Hormone replacement therapy, thyroid medications, acetaminophen

     

    Study Time Commitment: For participants who qualify based on screening evaluation, study participation will last for approximately 9 weeks. 

    In-house Stays

    Participants will stay at Prism Clinical Research two times. 

    • In-house Stay 1:  2 ½ days (2 overnights)
    • In-house Stay 2: 1 ½ days (1 overnight).  This stay will take place approximately 1 month after the first In-house stay

    Office Visits

    Each In-house stay is followed by a set of brief office visits.

    • In-house Stay 1 is followed by 9 office visits over the course of 4 weeks
    • In-house Stay 2 is followed by 10 office visits over the course of 4 weeks and one follow up phone call. 

    Compensation: Up to $2500

Please provide us with your contact information (below) and will get back to you as soon as possible.

If you have a general question, check Volunteer FAQ for an answer. If you're unsure of who to contact, please visit the Contact Us page.

Cancel